Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03883386 · ClinicalTrials.gov registry record · Phase 2
Loratadine for Improvement of Bone Pain in Patients With Chronic Granulocyte-Colony Stimulating Factor (G-CSF) Use
A Phase 2 study, sponsored by University of Michigan.
- Terminated
- Registry status
- Phase 2
- Development phase
- 3
- Enrollment target
NCT03883386 is a Phase 2 study that was terminated before completion, run by University of Michigan. The registered enrollment target is 3 participants.
The verdict
NCT03883386, a Phase 2 study, was terminated before completion, sponsored by University of Michigan.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 3 participants
- Enrollment target
Study Summary
G-CSF causes a release of histamine that may be a cause of chronic bone pain. Loratadine targets histamine, and so may be effective in reducing bone pain.The researchers plan to prospectively assess the effectiveness of loratadine for chronic bone pain in patients with chronic G-CSF use.
Interventions
- DRUG Placebo
- DRUG Loratadine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2019-06-24 |
| Est. Completion | 2019-10-18 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03883386
The ClinicalTrials.gov registry entry for NCT03883386 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 3 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Michigan, which has 1,327 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT03883386 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03883386 about?
NCT03883386 is a clinical study titled "Loratadine for Improvement of Bone Pain in Patients With Chronic Granulocyte-Colony Stimulating Factor (G-CSF) Use". G-CSF causes a release of histamine that may be a cause of chronic bone pain. Loratadine targets histamine, and so may be effective in reducing bone pain.The researchers plan to prospectively assess the effectiveness of loratadine for chronic bone pain in patients with chronic G-CSF use.
What is the current status of trial NCT03883386?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 3 participants. The study started on 2019-06-24. Estimated completion is 2019-10-18.
What interventions are being tested in trial NCT03883386?
The interventions under investigation include: Placebo (DRUG), Loratadine (DRUG).
Who is sponsoring clinical trial NCT03883386?
This trial is sponsored by University of Michigan, which has 1,327 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.